Keyphrases
Randomized Double-blind
100%
Glioblastoma
100%
Temozolomide
100%
Newly Diagnosed
100%
Phase II Trial
100%
EGFRvIII
100%
Rindopepimut
100%
Adverse Events
18%
Overall Survival
18%
Seizure
18%
Newly Diagnosed Glioblastoma
18%
Chemoradiation
18%
Keyhole Limpet Hemocyanin
18%
Brain Edema
18%
No Significant Difference
9%
Headache
9%
Median Overall Survival
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Pulmonary Embolism
9%
Cancer Treatment
9%
Serious Adverse Events
9%
Conventional Chemotherapy
9%
Interim Analysis
9%
Specific Peptide
9%
Thrombocytopenia
9%
Surgical Resection
9%
Young Males
9%
Male Patients
9%
Vaccine Target
9%
Minimal Residual Disease
9%
Residual Disease
9%
Intolerance
9%
Recursive Partitioning Analysis
9%
Treatment Allocation
9%
Combined Method
9%
Intradermal Injection
9%
Central Review
9%
European Organizations
9%
Block Size
9%
Deletion mutation
9%
MGMT Promoter Methylation
9%
Modified Intention-to-treat
9%
Enhancing Tumor
9%
CDX-110
9%
Medicine and Dentistry
Glioblastoma
100%
Temozolomide
100%
Rindopepimut
100%
Adverse Event
27%
Overall Survival
27%
Epileptic Seizure
18%
Chemoradiotherapy
18%
Brain Edema
18%
Minimal Residual Disease
18%
Keyhole Limpet Hemocyanin
18%
Neoplasm
9%
Headache
9%
Immunotherapy
9%
Promoter Region
9%
Pulmonary Embolism
9%
Cancer Treatment
9%
Intention-to-Treat Analysis
9%
Epidermal Growth Factor Receptor
9%
Thrombocytopenia
9%
Methylation
9%
Recursive Partitioning
9%
Granulocyte Macrophage Colony Stimulating Factor
9%
Interim Analysis
9%
Intradermal Drug Administration
9%
Surgery
9%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Glioblastoma
100%
Rindopepimut
100%
Adverse Event
27%
Overall Survival
27%
Chemoradiation Therapy
18%
Brain Edema
18%
Minimal Residual Disease
18%
Keyhole Limpet Hemocyanin
18%
Neoplasm
9%
Malignant Neoplasm
9%
Headache
9%
Chemotherapy
9%
Epidermal Growth Factor Receptor
9%
Granulocyte Macrophage Colony Stimulating Factor
9%
Immunotherapy
9%
Thrombocytopenia
9%
Lung Embolism
9%